Eloralintide is a long-acting amylin receptor agonist currently in clinical development for obesity, where it is used off-label for weight management and appetite regulation. Users typically run doses ranging from 500 µg to 12.5 mg daily, with 1.2 mg serving as the community modal dose and 1 mg representing the standard clinician-tier protocol. While reports of nausea, injection-site reactions, and sleep disturbances occasionally surface, the primary tradeoff is that the evidence base for non-obesity indications remains thin, and users lack an insurance pathway for coverage outside of the primary clinical indication.
Data last updated
Evidence shape
Eloralintide currently holds a moderate evidence tier, supported by exploratory human data focused primarily on obesity, where trials report a 9.0 percent change in body weight. While 15 trials are registered, the clinical landscape remains thin, with only one study providing posted results and the majority of the 263 total participants currently enrolled in active or recruiting research. The breadth of evidence is limited, as four of the five mapped indications rely on single-trial data, signaling that the peptide remains in the early stages of clinical validation without large-scale, multi-trial confirmation.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Obesity
−9.0 percent change7 studies · 2 completed
Overweight
5 studies · 1 completed
Pharmacokinetic / healthy volunteer studies
1 study
Sleep Apnea, Obstructive
1 study
3 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Anecdotal side effects
price offers can be sorted by column
How Eloralintide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
Across the three cited trials, the protocol used a fixed dose of 1 mg administered subcutaneously on a weekly schedule, with no reported variation in amount or frequency.
The clinician practice tier reports a subcutaneous dose of 1 mg taken once daily. No specific cycling schedule is documented in the available source.
Community users most often cite a typical dose of 1.2 mg, with a reported range from 0.5 mg to 12.5 mg; frequency is largely unspecified, though a few note daily dosing (1 mg) or every‑5‑day dosing (1.2 mg).